Compare TransMedics Group Inc (TMDX) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vistra Corp — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Vistra Corp trades at $162.44 (market cap $53.27B). The key difference: Vistra Corp is far larger — about 21× TransMedics Group Inc's market cap, and Vistra Corp pays a 0.58% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | VST | |
|---|---|---|
Market Cap | $2.54B | $53.27B |
Sector | Technology | Technology |
52-Week High | $150.42 | $217.92 |
52-Week Low | $61.99 | $134.71 |
Enterprise Value | $2.94B | $75.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Vistra Corp (VST) trades at $157.99, up 1.64% with strong institutional support and bullish technical signals. The stock shows robust fundamentals with 74.92% ROE and 11.52% net margin, though recent earnings were mixed with Q1 2026 beating expectations but Q3 and Q4 2025 missing. Analyst consensus remains overwhelmingly positive with 91% buy ratings and a $253 price target, representing 60% upside potential. Recent news highlights Vistra's positioning in the AI power infrastructure boom and long-term power purchase agreements with major tech companies.
Vistra presents significant growth potential driven by AI infrastructure demand and nuclear energy expansion, but faces risks from power price volatility and high debt levels. The company's diversified utility operations and strategic PPAs provide revenue stability, while technical indicators suggest continued upward momentum with key resistance at $159-$162. Investors should weigh the strong analyst support against execution risks in capital-intensive energy projects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
